Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 82

Sort by

Sort Order Select

Journal Articles

A Multicenter Real-World Analysis (RWA) of Primary Cutaneous Anaplastic Large Cell Lymphoma (PCALCL) Treated in the Modern Era

Deepa Jagadeesh, Stefan K. Barta, Jonathan E. Brammer, Wei Wei, Julie E Chang, Rahul Mishra, Tavakkoli Montreh, Alma Habib, Marcus P Watkins, Yash Deshmukh, Sharina C Macapagal, Madiha Iqbal, N. Nora Bennani, Frederick Lansigan, Neha Mehta-Shah

Blood (2023) 142 (Supplement 1): 6177.

https://doi.org/10.1182/blood-2023-191176

Published: 2023

Journal Articles

Safety Results of a Phase I Study of Zandelisib + R-CHOP in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL)

Deepa Jagadeesh, Paolo Caimi, Allison Winter, Wei Wei, Brad Pohlman, Christopher D'Andrea, Emily Rhoades, Robert M. Dean, Brian T. Hill

Blood (2023) 142 (Supplement 1): 6233.

https://doi.org/10.1182/blood-2023-191345

Published: 2023

Journal Articles

A Retrospective Study of Patient Characteristics, Treatment Patterns and Outcomes in Patients with Primary CNS Lymphoma

Thomas Curley, Wei Wei, Christine Cordova, David Peereboom, Mina Lobbous, Allison Winter

Blood (2023) 142 (Supplement 1): 4492.

https://doi.org/10.1182/blood-2023-190843

Published: 2023

Journal Articles

Resource Utilization Analysis of Two Algorithms for Hematopoietic Progenitor Cell Mobilization in Multiple Myeloma

Daniel Cancilla, Daniel (Paul) Nurse, Wei Wei, Christina Ferraro, Brian Matia, Julie Coffman, Craig S Sauter, Betty K. Hamilton, Jack Khouri

Blood (2023) 142 (Supplement 1): 6942.

https://doi.org/10.1182/blood-2023-178831

Published: 2023

Journal Articles

Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma

Zhihui Song, Wenjun Wu, Wei Wei, Wenming Xiao, Michelle Lei, Kathy Q. Cai, Da Wei Huang, Subin Jeong, Jing-Ping Zhang, Hongbo Wang, Marshall E. Kadin, Thomas A. Waldmann, Louis M. Staudt, Masao Nakagawa, Yibin Yang

Blood (2023) 142 (15): 1297–1311.

https://doi.org/10.1182/blood.2022019166

Published: 2023

Includes: Supplemental data

Journal Articles

Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score

Rajshekhar Chakraborty, Lisa Rybicki, Wei Wei, Jason Valent, Beth M. Faiman, Christy J. Samaras, Faiz Anwer, Alok A. Khorana

Blood (2022) 140 (23): 2443–2450.

https://doi.org/10.1182/blood.2022015727

Published: 2022

Includes: Supplemental data

Journal Articles

Efficacy of the Hepcon System in Reducing Hemorrhagic and Thrombotic Complications in Antiphospholipid Syndrome Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass

Michael Sheu, Wei Wei, Lauren M Granat, John Apostolakis, Patrick M Grady, Dana E. Angelini

Blood (2022) 140 (Supplement 1): 2821–2822.

https://doi.org/10.1182/blood-2022-167029

Published: 2022

Journal Articles

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions

Blood (2022) 140 (Supplement 1): 8019–8021.

https://doi.org/10.1182/blood-2022-167411

Published: 2022

Journal Articles

A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure

Jan Philipp Bewersdorf, Rory Michael Shallis, Elad Sharon, Anne Caldwell, Wei Wei, Abdulraheem Yacoub, Yazan F. Madanat, Joshua F. Zeidner, Jessica K. Altman, Olatoyosi Odenike, Swaroopa Yerrabothala, Tibor Kovacsovics, Nikolai A. Podoltsev, Stephanie Halene, Richard F. Little, Richard Piekarz, Steven D. Gore, Tae Kon Kim, Amer M. Zeidan

Blood (2022) 140 (Supplement 1): 9084–9086.

https://doi.org/10.1182/blood-2022-158626

Published: 2022

Journal Articles

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimen for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Blood (2022) 140 (Supplement 1): 12637–12639.

https://doi.org/10.1182/blood-2022-169057

Published: 2022

Journal Articles

Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy

Blood (2022) 140 (Supplement 1): 7086–7087.

https://doi.org/10.1182/blood-2022-168109

Published: 2022

Journal Articles

External Validation of the Saved Score for Venous Thromboembolism Risk Stratification in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs

Danai Dima, Ang Li, Lauren M. Granat, Puneet Dhillon, Carmelo Gurnari, Anirudh Yalamanchali, Saeid Mirzai, Wei Wei, Beth M. Faiman, Louis S. Williams, Sandra Mazzoni, Christy J. Samaras, Faiz Anwer, Jason Valent, Jack Khouri

Blood (2022) 140 (Supplement 1): 11299–11300.

https://doi.org/10.1182/blood-2022-165722

Published: 2022

Journal Articles

Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 7308–7310.

https://doi.org/10.1182/blood-2022-166325

Published: 2022

Journal Articles

Risk of Venous Thromboembolism and Survival Outcomes in Patients with Lymphoma

Doaa Attia, Wei Wei, Mailey L. Wilks, Christopher D'Andrea, Alok A Khorana, Dana E. Angelini

Blood (2021) 138 (Supplement 1): 4262.

https://doi.org/10.1182/blood-2021-152321

Published: 2021

Journal Articles

Quantitative Assessment of the Evolution of Therapeutic Target Antigen Expression Level in Diffuse Large B-Cell Lymphoma in Response to Treatment

Agrima Mian, Narendra Bhattarai, Wei Wei, Manishkumar S. Patel, Paolo F. Caimi, Sarah L. Ondrejka, Brian T. Hill

Blood (2021) 138 (Supplement 1): 4367.

https://doi.org/10.1182/blood-2021-149727

Published: 2021

Journal Articles

Lenalidomide Versus Thalidomide or Bortezomib As Maintenance Regimens for Non-Transplant Patients with Multiple Myeloma: Multi-Center Real World Experience in China

Zhe Zhuang, Lei Shi, Ying Tian, Dongmei Zou, Ru Feng, Fei Dong, Yanping Ma, Hong Yu, Wei-wei Tian, Shuangjiao Liu, Liangming Ma, Rong Fu, Hongmei Jing, Hui Liu, Wanling Sun, Chen Wenming, Yin Wu, Li Bao, Junling Zhuang

Blood (2021) 138 (Supplement 1): 4728.

https://doi.org/10.1182/blood-2021-149502

Published: 2021

Journal Articles

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimens for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Blood (2021) 138 (Supplement 1): 4766.

https://doi.org/10.1182/blood-2021-152542

Published: 2021

Journal Articles

Risk of Venous Thromboembolism in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors

Doaa Attia, Wei Wei, Nathan A Pennell, Keith R. McCrae, Alok A Khorana, Pradnya Patil

Blood (2021) 138 (Supplement 1): 3223.

https://doi.org/10.1182/blood-2021-153659

Published: 2021

Journal Articles

Identification of Pre-Gmps and Pre-Meps: Two Novel Types of Committed Progenitor Cells in Bone Marrow

Ryan Mack, Lei Zhang, Kanak Joshi, Shanhui Liu, Mark Sellin, Wei Wei, Peter Breslin, Jiwang Zhang

Blood (2021) 138 (Supplement 1): 3266.

https://doi.org/10.1182/blood-2021-153800

Published: 2021

Journal Articles

Elucidating the Importance and Regulation of Key Enhancers for Human MEIS1 Expression

Xining Yang, Ping Xiang, Leo Escano, Ishpreet Dhillon, Edith Schneider, Jack Clemans-Gibbon, Wei Wei, Jasper Wong, Simon Xufeng Wang, Gregg Morin, Pamela A Hoodless, Martin Hirst, Aly Karsan, Florian Kuchenbauer, R. Keith Humphries, Arefeh Rouhi

Blood (2021) 138 (Supplement 1): 3302.

https://doi.org/10.1182/blood-2021-151467

Published: 2021

NARROW

A Multicenter Real-World Analysis (RWA) of Primary Cutaneous Anaplastic Large Cell Lymphoma (PCALCL) Treated in the Modern Era

Safety Results of a Phase I Study of Zandelisib + R-CHOP in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL)

A Retrospective Study of Patient Characteristics, Treatment Patterns and Outcomes in Patients with Primary CNS Lymphoma

Resource Utilization Analysis of Two Algorithms for Hematopoietic Progenitor Cell Mobilization in Multiple Myeloma

Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma

Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score

Efficacy of the Hepcon System in Reducing Hemorrhagic and Thrombotic Complications in Antiphospholipid Syndrome Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions

A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimen for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy

External Validation of the Saved Score for Venous Thromboembolism Risk Stratification in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs

Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

Risk of Venous Thromboembolism and Survival Outcomes in Patients with Lymphoma

Quantitative Assessment of the Evolution of Therapeutic Target Antigen Expression Level in Diffuse Large B-Cell Lymphoma in Response to Treatment

Lenalidomide Versus Thalidomide or Bortezomib As Maintenance Regimens for Non-Transplant Patients with Multiple Myeloma: Multi-Center Real World Experience in China

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimens for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Risk of Venous Thromboembolism in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors

Identification of Pre-Gmps and Pre-Meps: Two Novel Types of Committed Progenitor Cells in Bone Marrow

Elucidating the Importance and Regulation of Key Enhancers for Human MEIS1 Expression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only